Preclinical and early clinical research on Trametes versicolor (PSK/PSP), Chaga, and Lion’s Mane shows these mushrooms can inhibit breast cancer cell growth, trigger apoptosis, and boost natural killer cell activity — with Trametes versicolor's polysaccharide-K having the strongest human evidence as an adjuvant alongside, never instead of, conventional treatment.
Breast cancer is now the most commonly diagnosed cancer in women worldwide, with roughly 2.3 million new cases recorded globally in 2022 (WHO GLOBOCAN, 2022). Several medicinal mushrooms have documented laboratory and clinical evidence relevant to breast cancer care: PSK/PSP from Trametes versicolor improved disease-free survival in Japanese adjuvant trials, while Lion’s Mane and Chaga extracts have induced apoptosis in MCF-7 breast cancer cells in laboratory studies. None of these mushrooms are a substitute for surgery, chemotherapy, radiation, or hormone therapy — the evidence supports them as complementary, not primary, care.
Breast Cancer: A Growing Global Health Crisis
Breast cancer overtook lung cancer as the most frequently diagnosed cancer worldwide, with an estimated 2.3 million new cases and roughly 670,000 deaths recorded in 2022 (WHO GLOBOCAN, 2022). Standard treatments — chemotherapy, hormone therapy, surgery, and radiation — remain the backbone of care, but each carries side effects that can erode quality of life during and after treatment. That reality is what drives ongoing research into complementary approaches, including medicinal mushrooms, that might reduce treatment burden, support immune recovery, or add a modest survival benefit when used alongside conventional oncology care rather than in place of it.Medicinal Mushrooms in Breast Cancer Research
Medicinal mushrooms have a centuries-long history of use in East Asian medicine, particularly in Japan and China, and interest in them has grown steadily in Western integrative oncology over the past two decades. Researchers have focused on a handful of species with documented antitumor, antioxidant, and immunomodulatory activity, testing extracts in cell cultures, animal models, and — in a smaller number of cases — human clinical trials. The sections below summarize what the evidence for each mushroom actually shows, including where it's strong and where it's still preliminary.Lion's Mane (Hericium erinaceus) for Breast Cancer Prevention
Hericium erinaceus contains bioactive compounds including polysaccharides, hericenones, and erinacins, which together show antioxidant, anti-inflammatory, immunomodulatory, and anti-metastatic activity in laboratory research. A 2021 study published in the International Journal of Medicinal Mushrooms treated MCF-7 estrogen-receptor-positive breast cancer cells with Lion’s Mane water extract and found it inhibited cell viability in a dose- and time-dependent manner, while inducing apoptosis and arresting cells at the G1 phase of the cell cycle.The same study found the extract acted synergistically with tamoxifen, a standard hormone therapy drug, suggesting a possible complementary role rather than a standalone effect. Whole-genome transcriptome analysis in this research pointed to disruption of cell-cycle and survival-signaling pathways as the likely mechanism, though this remains cell-culture evidence and hasn't yet been tested in human breast cancer patients.Chaga Mushroom (Inonotus obliquus) Anticancer Properties
Chaga's main active compounds — triterpenoids such as inotodiol and betulinic acid derivatives, along with polysaccharides and phenolics — show strong antioxidant activity that helps counter oxidative stress linked to tumor development. Laboratory research has found Chaga extract fractions induce cell-cycle arrest and apoptosis in MCF-7 breast cancer cells through the p53/p21 signaling pathway, a well-documented tumor-suppressor route.A separate line of research found Chaga extract activates autophagy in breast cancer cells via the AMPK-mTOR pathway, a mechanism that can push cancer cells toward self-destruction under metabolic stress. Animal research has also shown that continuous oral intake of Chaga aqueous extract suppressed tumor progression in mice while preserving normal body temperature, a marker of reduced treatment-related toxicity (Arata et al., Fungal Biol, 2016). As with Lion’s Mane, this evidence base is still preclinical, and no controlled human trials in breast cancer patients have been published to date.Trametes Versicolor for Immune Modulation
Trametes versicolor (turkey tail) is the best-studied mushroom in this list when it comes to human breast cancer data. Its main active compounds — the polysaccharide-K (PSK, sold in Japan as Krestin) and polysaccharopeptide (PSP) — stimulate natural killer cell activity and lymphocyte counts, and PSK holds approved adjuvant drug status in Japan for several cancers.A Japanese multicenter randomized trial (Nishinihon Cooperative Study Group, ACETBC) tested PSK alongside standard chemoendocrine therapy in stage II breast cancer patients and reported improved outcomes in the PSK-treated arm compared with chemotherapy alone. More recently, a US-based Phase 1 dose-escalation trial gave turkey tail extract (3–9 grams/day) to women recovering from breast cancer radiotherapy and found the mushroom well tolerated, with increased lymphocyte counts and natural killer cell activity at the 6-gram dose (Torkelson et al., ISRN Oncology, 2012). This is meaningfully stronger evidence than exists for most other medicinal mushrooms, though it still describes immune support alongside treatment, not a cure.Shiitake Mushroom (Lentinula edodes) and Lentinan's Cancer-Fighting Role
Shiitake mushroom contains bioactive polysaccharides, glycoproteins, and the compound lentinan, which has antioxidant, immunomodulatory, and antitumor properties. Lentinan's clinical evidence base comes mainly from gastric cancer trials in Japan, where it extended survival when combined with chemotherapy, and its immune-stimulating mechanism — activating macrophages and T-cells — is considered broadly relevant across tumor types.Direct human trial data specific to breast cancer is limited compared with PSK, but laboratory studies of shiitake extracts have shown reduced proliferation, invasion, and migration in cultured cancer cells, consistent with the general antitumor pattern seen across polysaccharide-rich medicinal mushrooms. Researchers view shiitake's strongest evidence-backed role as general immune support during and after cancer treatment rather than a breast-cancer-specific therapy.Red Amanita (Amanita muscaria) in Cancer Supportive Care
Amanita muscaria contains muscimol, ibotenic acid, polysaccharides, and other bioactive compounds that have shown antitumor and apoptosis-inducing activity in early laboratory research, alongside a long history of traditional use in parts of Siberia and Northern Europe.This evidence base is considerably earlier-stage than the data for Trametes versicolor or Lion’s Mane — it consists mainly of cell-culture and traditional-use reports rather than the controlled human or animal trials available for the other mushrooms on this list. Amanita muscaria's better-documented effects relate to stress reduction and pain modulation, which some patients find helpful for coping with the physical and emotional toll of cancer treatment, even though this doesn't constitute antitumor evidence in its own right.What the Evidence Actually Shows
Taken together, this research places these five mushrooms at different points on the same evidence spectrum. Trametes versicolor sits furthest along, with a Japanese adjuvant approval and human trial data from both Japan and the United States. Lion’s Mane and Chaga have specific, mechanistically detailed MCF-7 breast cancer cell studies, which is more targeted evidence than most medicinal mushrooms can claim, but neither has been tested in breast cancer patients directly. Shiitake's strongest evidence lies outside breast cancer specifically, and Amanita muscaria's antitumor evidence is the earliest-stage of the group. None of this rises to the level of a proven breast cancer treatment or prevention strategy — it's a research signal worth watching, not a substitute for oncology care.How to Use Medicinal Mushrooms Safely Alongside Cancer Treatment
If you have been diagnosed with breast cancer, talk to your oncology team before adding any mushroom extract to your routine — some polysaccharides can interact with chemotherapy or immunotherapy drugs, and your care team needs the full picture. Used this way, as a complement to standard treatment rather than a replacement for it, the mushrooms above may help support immune function, manageable side effects, and general quality of life during and after treatment. For those without a cancer diagnosis, some people also use these mushrooms as part of a broader wellness routine, though there's no clinical evidence that they prevent breast cancer from developing in healthy individuals.You can also buy them in our store.1.Amanita fruits
2.Amanita capsules
3.Amanita extract
4.Mushroom ground
5.Lion's mane fruits
6.Lion's mane capsules
7.Lion's mane extract
8.Chaga chunks
9.Chaga extract
10.Trametes versicolor extract
11.Shiitake mushroom
Frequently Asked Questions
Can medicinal mushrooms prevent or cure breast cancer?
No. Current evidence comes mainly from laboratory studies and a small number of human immune-support trials, primarily with Trametes versicolor. These mushrooms may support the immune system and complement conventional treatment, but they haven't been shown to prevent breast cancer or replace standard oncology care.
Which medicinal mushroom has the strongest evidence for breast cancer?
Trametes versicolor (turkey tail), through its PSK and PSP compounds, has the most human clinical evidence, including a Japanese adjuvant trial and a US Phase 1 dose-escalation trial showing improved immune markers in breast cancer patients (Torkelson et al., 2012).
Is it safe to take medicinal mushrooms during chemotherapy?
Always consult your oncology team first. Some mushroom polysaccharides stimulate the immune system and could interact with chemotherapy, radiotherapy, or hormone therapy, so professional guidance is essential before combining them with active cancer treatment.
Do Lion's Mane and Chaga actually kill breast cancer cells?
Laboratory studies have shown both mushrooms induce apoptosis in MCF-7 breast cancer cells and inhibit cell viability in a dose-dependent manner. This is promising cell-culture evidence, but neither mushroom has yet been tested in breast cancer patients in a published clinical trial.
How are medicinal mushrooms typically used for cancer support?
They're most commonly taken as extracts, tinctures, capsules, or dried fruiting body powder, alongside — never instead of — conventional treatment. Dosing varies by mushroom and preparation, so guidance from an oncologist or integrative medicine practitioner is recommended.
Related Articles
- Guide to Medicinal Mushrooms
- Mushrooms in Supportive Oncology Treatment
- Mushroom Supplements: A Complete Guide
Sources
- Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002. PMID 12242575
- Patel S, Goyal A. Recent developments in mushrooms as anti-cancer therapeutics. 3 Biotech. 2012. PMID 28324347
- World Health Organization. Global Cancer Observatory (GLOBOCAN): Breast Cancer Fact Sheet. 2022. gco.iarc.who.int
- Transcriptome-wide analysis reveals the molecular mechanism of tumoricidal effects of Lion's Mane medicinal mushroom, Hericium erinaceus, on MCF-7 breast cancer cells. Int J Med Mushrooms. 2021;23(1):91-106.
- Arata S, et al. Continuous intake of the Chaga mushroom (Inonotus obliquus) aqueous extract suppresses cancer progression and maintains body temperature in mice. Heliyon. 2016. PMID 27441282
- Torkelson CJ, Sweet E, Martzen MR, et al. Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncology. 2012. PMC3369477
- Trametes versicolor (turkey tail mushrooms) and the treatment of breast cancer. Anticancer Agents. 2016. PMID 27257526